STATEMENTS OF OPERATIONS (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Genetic testing	$ 1,641,490	$ 2,168,744
Other	168,828	260,868
Total revenue	1,810,318	2,429,612
Cost of revenue	1,435,377	1,632,497
Gross profit	374,941	797,115
Operating expenses:
Research and development	843,102	721,568
Selling, general and administrative	5,767,138	6,564,807
Amortization of intangibles	94,100	109,266
Total operating expenses	6,704,340	7,395,641
Loss from operations	(6,329,399)	(6,598,526)
Other income (expense):
Interest income	4,935	6,804
Interest expense	(11,250)	(472,186)
Gain on disposal of asset	0	5,975
Total other income (expense)	(6,315)	(459,407)
Loss before income taxes	(6,335,714)	(7,057,933)
Benefit for income taxes	0	0
Net loss	$ (6,335,714)	$ (7,057,933)
Basic and diluted net loss per common share	$ (0.05)	$ (0.08)
Weighted average common shares outstanding, basic and diluted	123,768,139	90,449,758